Virtus Investment Advisers’s Soleno Therapeutics SLNO Stock Holding History

Virtus Investment Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,243	Closed	-$176K	–	505
2026 Q1	$176K	Buy	5,243 +127	+2%	+$4.98K	0.05%	433
2025 Q4	$237K	Buy	5,116 +3,697	+261%	+$203K	0.06%	352
2025 Q3	$95.9K	Buy	1,419 +247	+21%	+$18.3K	0.03%	428
2025 Q2	$98.2K	Sell	1,172 -2,371	-67%	-$177K	0.03%	341
2025 Q1	$253K	Buy	+3,543	New	+$173K	0.07%	252

Virtus Investment Advisers's SLNO Position: Q2 2026 in Review

Virtus Investment Advisers sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 5,243 shares — an estimated $176K sold.

Virtus Investment Advisers first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $253K in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Virtus Investment Advisers reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtus Investment Advisers sold 5,243 Soleno Therapeutics shares in Q2 2026, an estimated $176K.
Virtus Investment Advisers first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
Virtus Investment Advisers's Soleno Therapeutics position peaked at $253K in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.